XML 90 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Funding Arrangement - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 30, 2021
Jul. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jan. 31, 2022
Aug. 04, 2021
Jul. 31, 2020
Funding Arrangement [Line Items]                
Grant income     $ 1,585,000 $ 2,478,000 $ 237,000      
Cost Reimbursement Sub-Award Agreement                
Funding Arrangement [Line Items]                
Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria   4 years            
Potential funding amount of award to develop vaccine to prevent shingella infections $ 500,000              
Grant income     1,600,000 2,500,000 $ 200,000      
Cost Reimbursement Sub-Award Agreement | Maximum                
Funding Arrangement [Line Items]                
Initial funding committed by award   $ 1,600,000            
Total funding committed by award, available upon achievement of development milestones   $ 15,100,000            
Potential funding period of award to develop vaccine to prevent shingella infections 5 years              
CARB-X Agreement                
Funding Arrangement [Line Items]                
Additional funding committed by award             $ 3,200,000  
Grant receivable on unreimbursed, eligible costs incurred     $ 1,200,000 $ 300,000        
CARB-X Agreement | Subsequent Event                
Funding Arrangement [Line Items]                
Potential funding committed by award           $ 13,900,000    
CARB-X Agreement | Maximum                
Funding Arrangement [Line Items]                
Initial funding committed by award               $ 2,700,000
Additional funding committed by award             3,200,000  
Potential funding committed by award             $ 29,700,000  
CARB-X Agreement | Minimum                
Funding Arrangement [Line Items]                
Initial funding committed by award               $ 1,600,000